Logo

Aquestive Therapeutics' Exservan (riluzole) Receives the US FDA Approval to Treat Amyotrophic Lateral Sclerosis (ALS)

Share this

Aquestive Therapeutics' Exservan (riluzole) Receives the US FDA Approval to Treat Amyotrophic Lateral Sclerosis (ALS)

Shots:

  • Exservan (riluzole) Oral Film received the US FDA approval and has also received FDA’s ODD in Jan 2019 and has been evaluated to assess PK bioequivalence to the Rilutek
  • The ODD is granted to novel drugs and biologics which are intended for the safe and effective treatment- diagnosis or prevention of rare diseases affecting people less than 200-000 in the US
  • Exservan (50mg) is an Oral film formulation of approved glutamate Inhibitor riluzole applied on top of the tongue where it adheres and dissolves

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Twitter


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions